The Magazine for Sleep Professionals
Saturday, August 22, 2026
Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis. SPIRO-2101, an inhaled […]
The Cystic Fibrosis Foundation announced data from a collaborative, international effort to understand the impact of COVID-19 on people with cystic fibrosis, a genetic disease that impacts the lungs and other organs. The manuscript, published in the Journal of Cystic Fibrosis, reports on 40 people with CF across eight countries […]
Electromed, Inc. has announced the launch of its SmartVest Connect® App for iOS and Android, a personalized high-frequency chest wall oscillation (HFCWO) therapy management portal for patients with compromised pulmonary function. The SmartVest Connect app securely connects to the SmartVest® SQL® through Bluetooth™ technology. This interface allows patients and healthcare teams to […]
Synspira Therapeutics Inc. has signed an agreement with the Cystic Fibrosis Foundation to support the development of SNSP003, Synspira’s orally delivered non-porcine enzyme replacement therapy (ERT) designed to treat Malabsorption Syndromes. Malabsorption Syndromes are a group of life-threatening disorders that result from defects in the digestion and absorption of macronutrients […]
In adolescent and adult patients with cystic fibrosis taking lumacaftor-ivacaftor (ORKAMBI®), the combination drug appears to improve lung function and body weight and reduce the need for intravenous antibiotic treatment, according to a French study published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. However, […]
Patients with cystic fibrosis who take ivacaftor appear to have fewer respiratory infections over time than those not taking the drug, according to new research published online in the Annals of the American Thoracic Society. Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor […]
International Biophysics Corporation, manufacturer of the AffloVest is committed to raising awareness of Cystic Fibrosis and the importance of airway clearance therapy in the management of the disease. Over 30,000 people in the U.S. and 70,000 worldwide struggle with the effects of cystic fibrosis every day. There is no cure […]
May is National Cystic Fibrosis (CF) Awareness Month. More than 30,000 adults and kids in the United States have CF. In Georgia, a CF survivor is currently winning her 35-year battle with the disease — thanks to her life-saving double lung transplant. Today, on May Day, she and her husband […]
A pioneering approach to cystic fibrosis (CF) care saves on the cost and inconvenience of frequent hospital visits and could help detect changes in lung function sooner. These results come from a pilot study involving people with CF who are being treated at London’s Royal Brompton Hospital. The results come […]
Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF […]
